Division of Cardiology, Duke University School of Medicine, Durham, North Carolina; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; School of Medicine, University of Adelaide, SA, Australia.
J Card Fail. 2024 Oct;30(10):1330-1342. doi: 10.1016/j.cardfail.2024.08.002.
Patients with heart failure (HF) and underlying coronary artery disease (CAD) have a substantially higher risk of mortality compared with those with HF from other causes. However, identifying individuals with HF for whom revascularization is likely to improve prognosis is a complex clinical decision. Revascularization is likely beneficial for patients with CAD-predominant symptoms, such as those with acute myocardial infarction or stable ischemic heart disease with refractory angina. However, for patients with HF-predominant symptoms, characterized by dyspnea without acute myocardial infarction or refractory angina, the benefits of revascularization are less clear. This state-of-the-art review summarizes the outcomes, clinical trials, and therapeutic approaches for patients with both CAD and HF, and proposes a therapeutic algorithm to guide the diagnosis and comprehensive workup of these complex patients.
患有心力衰竭(HF)和潜在冠状动脉疾病(CAD)的患者的死亡率明显高于其他原因引起的 HF 患者。然而,确定哪些 HF 患者进行血运重建可能会改善预后是一个复杂的临床决策。血运重建可能对以 CAD 为主的症状的患者有益,例如急性心肌梗死或稳定性缺血性心脏病伴难治性心绞痛的患者。然而,对于以 HF 为主的症状的患者,其特征是呼吸困难而无急性心肌梗死或难治性心绞痛,血运重建的益处不太明确。本文全面综述了 CAD 和 HF 并存患者的结局、临床试验和治疗方法,并提出了一个治疗算法来指导这些复杂患者的诊断和综合评估。